Insulin potentiating effect on development of alloxan diabetes and its prevention by the Ca-channel blocker nicardipine.
Katsumata
K
K
Katsumata Hospital, Nagoya, Japan.
Miyao
M
M
Katsumata
Y
Y
D000496:Alloxan / Q000494:pharmacology*; D000818:Animals; D001786:Blood Glucose; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced* / Q000188:drug therapy / Q000378:metabolism; D004357:Drug Synergism; D005215:Fasting; D005609:Free Radicals / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000494:pharmacology*; D008297:Male; D009529:Nicardipine / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
D001786:Blood Glucose; D002121:Calcium Channel Blockers; D005609:Free Radicals; D007004:Hypoglycemic Agents; D007328:Insulin; D000496:Alloxan; D009529:Nicardipine